Who is sponsoring NCT05919966?

NCT05919966 is sponsored by National Taiwan University Hospital.

What drugs are being tested in NCT05919966?

Interventions in NCT05919966: Chlorhexidine bathing.

What condition does NCT05919966 study?

NCT05919966 studies Central Line-associated Bloodstream Infection (CLABSI).

Is NCT05919966 still recruiting?

NCT05919966 is currently completed. Last updated 27 June 2023.

Last reviewed 2023-06-27 · How we verify

NCT05919966

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Association Between Chlorhexidine Bathing and Central Line-Associated Infections in Medical Intensive Care Units

Completed Last updated 27 June 2023

What this trial tests

trial testing Chlorhexidine bathing in Central Line-associated Bloodstream Infection (CLABSI) in 6,930 participants. Completed in 30 May 2023.

Timeline

12 April 2023

Primary endpoint
30 April 2023

30 May 2023

Quick facts

Lead sponsor	National Taiwan University Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	6,930
Start date	12 April 2023
Primary completion	30 April 2023
Estimated completion	30 May 2023
Sites	1 location across Taiwan

Drugs / interventions tested

Chlorhexidine bathing

Conditions studied

Central Line-associated Bloodstream Infection (CLABSI) — all drugs for Central Line-associated Bloodstream Infection (CLABSI) →

Sponsor

National Taiwan University Hospital

Who can join

18 and older, any sex, with Central Line-associated Bloodstream Infection (CLABSI). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

We conducted a retrospective observational cohort study assessing the relationship between regular bathing using 2% CHG wipes every other day and the occurrence of central line-associated infections (CLABSI) in patients within the medical intensive care unit (MICU).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Central Line-associated Bloodstream Infection (CLABSI)

Currently open trials in the same condition.

NCT06458231 — Determining the Prevalence of Primary and Secondary Central Line Associated Blood Stream Infection (CLABSI) at the Terti · recruiting

Other National Taiwan University Hospital trials

Trials by the same sponsor.

NCT06936917 — Timing for Computed Tomography and Post-Resuscitation Care on Short-Term Outcomes in Out-of-Hospital Cardiac Arrest · not yet recruiting
NCT05396222 — A Prospective Study of the Safety and Efficacy of 3D-printed Non-rigid Biomimetic Implant in Cervical and Thoracolumbar · NA · not yet recruiting
NCT07532356 — Integrating Tumor Genomics and Urinary Exosomal Proteomics to Establish a Multi-Layer Biomarker Framework for Early Risk · not yet recruiting
NCT07317310 — The NTU JO-SMART Study · NA · not yet recruiting
NCT07382024 — Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05919966 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Taiwan University Hospital
Last refreshed: 27 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05919966.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing